DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: NOVANTRONE (mitoxantrone)
       *****************************************************
       #Post#: 701--------------------------------------------------
       (Abst.) Therapy-related acute leukemia w/Novantrone...limiting
       the risk
   DIR By: agate
       Date: March 30, 2015, 9:54 am
       ---------------------------------------------------------
       From Multiple Sclerosis Journal, March 30, 2015:
       --- Quote ---
       > Therapy-related acute leukaemia with mitoxantrone: Four years
       on, what is the risk and can it be limited?
       >
       > Richard Ellis
       > The Walton Centre for Neurology and Neurosurgery, UK
       > Sean Brown
       > Countess of Chester, Chester, UK
       >
       > Mike Boggild
       > Townsville Hospital, Queensland, Australia
       > The Walton Centre for Neurology and Neurosurgery, Lower Lane,
       Fazakerley, Liverpool, L9 7LJ, UK rjbellis@doctors.org.uk
       >
       > Therapy-related acute leukaemia (TRAL) is a significant
       concern, when considering treatment with mitoxantrone for
       multiple sclerosis (MS). We re-evaluated the literature,
       identifying all case reports and series of > 50 patients
       reporting TRAL cases in MS. TRAL was diagnosed in 0.73% of the
       12,896 patients identified. Median onset was 22 months following
       treatment. We calculated a number needed to harm of 137.5
       exposed patients, significantly higher than our 2008 analysis.
       >
       > We found that 82.8% of patients were exposed to > 60 mg/m2
       with a relative risk of 1.85 (p = 0.018) compared to < 60mg/m2,
       strongly suggesting a relationship to dose. MS treatment
       regimens which limit the mitoxantrone dose to < 60mg/m2 reduce
       the risk of TRAL.
       --- End Quote ---
       *****************************************************
       Page 1 of 1